- Cystatin C assays, used to evaluate kidney function by measuring the cystatin C protein in blood, are gaining prominence as a reliable alternative to traditional creatinine-based diagnostics due to their higher accuracy and independence from muscle mass variations
- The growing demand for cystatin C assays is primarily driven by the rising global burden of chronic kidney disease (CKD), diabetes, and cardiovascular disorders, along with increased clinical awareness about the limitations of existing renal biomarkers
- North America dominated the cystatin C assay market with the largest revenue share of 39.5% in 2024, attributed to advanced healthcare infrastructure, high adoption of novel diagnostic methods, and strong focus on early disease detection, particularly in the U.S., where clinical guidelines increasingly recommend cystatin C testing for enhanced GFR estimation
- Asia-Pacific is expected to be the fastest growing region in the cystatin C assay market during the forecast period due to expanding healthcare access, increasing prevalence of renal conditions, and growing investments in diagnostic technologies
- The ELISA segment dominated the cystatin C assay market with a market share of 46.5% in 2024, driven by its widespread clinical usage, cost-effectiveness, and compatibility with automated laboratory systems
